Immediate intraocular pressure changes following intravitreal dexamethasone implant

Journal of Ocular Pharmacology and Therapeutics

Volumn 32, Issue 1, 2016, Pages 44-49

  Alagöz, Neşe ^a   Alagöz, Cengiz ^a   Yllmaz, Ihsan ^a   Ylldlrlm, Yusuf ^a   Baz, Ökkeş ^a   Altan, Çiʇdem ^a   Yazlcl, Ahmet Taylan ^a   Taşkaplll, Muhittin ^a  

^a Beyoglu Eye Training and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT;

ADULT; APPLANATION TONOMETER; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DIABETIC RETINOPATHY; FEMALE; HUMAN; IMPLANTATION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MACULAR EDEMA; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION; DRUG EFFECTS; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; RETINAL VEIN OCCLUSION;

DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84955265401     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2015.0087     Document Type: Article

References (27)

1. Jonas, J.B. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol. Scand. 83: 645-663, 2005
2. McAllister, I.L., Vijayasekaran, S., Chen, S.D., and Yu, D.Y. Effect of triamcinolone acetonide on vascular endothelial growth factor and occluding levels in branch retinal vein occlusion. Am. J. Ophthalmol. 147: 838-846, 2009
3. Lee, S.S., Hughes, P., Ross, A.D., et al. Biodegradable implants for sustained drug release in the eye. Pharm. Res. 27: 2043-2053, 2010
4. London, N.J., Chiang, A., and Haller, J.A. The dexamethasone drug delivery system: indications and evidence. Adv. Ther. 28: 351-366, 2011
5. Lee, E.W., Hariprasad, S.M., Mieler, W.F., Newman, T.L., and Apte, R.S. Short-Term intraocular pressure trends after intravitreal triamcinolone injection. Am. J. Ophthalmol. 143: 365-367, 2007
6. Gismondi, M., Salati, C., Salvetat, M.L., Zeppieri, M., and Brusini, P. Short-Term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J. Glaucoma. 18: 658-661, 2009
7. Hollands, H., Wong, J., Bruen, R., Campbell, R.J., Sharma, S., and Gale, J. Short-Term intraocular pressure changes after intravitreal injection of bevacizumab. Can. J. Ophthalmol. 42: 807-811, 2007
8. Kim, J.E., Mantravadi, A.V., Hur, E.Y., and Covert, D.J. Short-Term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 146: 930-934, 2008
9. Hoang, Q.V., Tsuang, A.J., Gelman. R., et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 33: 179-187, 2013
10. Meyer, L.M., and Schönfeld, C.L. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J. Ocul. Pharmacol. Ther. 29: 560-565, 2013
11. Mayer, W.J., Wolf, A., Kernt, M., et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 27: 816-822, 2013
12. Boyer, D.S., Yoon, Y.H., Belfort Jr., R., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 12: 1904-1914, 2014
13. Meyer, C.H., Liu, Z., Brinkmann, C.K., Rodrigues, E.B., and Bertelmann, T.; German Retinal Vein Occlusion Group. Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO study. J. Ocul. Pharmacol. Ther. 30: 387-391, 2014
14. Coden, D.J., Freeman, W.R., and Weinreb, R.N. Intraocular pressure response after pneumatic retinopexy. Ophthalmic. Surg. 19: 667-996, 1988
15. Tsui, Y.P., Chiang, C.C., and Tsai, Y.Y. Paracentesis before intravitreal injection of bevacizumab. Can. J. Ophthalmol. 43: 239, 2008
16. Frenkel, M.P., Haji, S.A., and Frenkel, R.E. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch. Ophthalmol. 128: 1523-1527, 2010
17. Boon, C.J., Crama, N., Klevering, B.J., van Kuijk, F.J., and Hoygn, C.B. Reflux after intravitreal injection of bevacizumab. Ophthalmology. 115: 1270, 2008
18. Rodrigues, E.B., Meyer, C.H., Grumann Jr., A., et al. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am. J. Ophthalmol. 143: 1035-1037, 2007
19. Knecht, P.B., Michels, S., Sturm, V., Bosch, M.M., and Menke, M.N. Tunneled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina. 29: 1175-1181, 2009
20. Ozkaya, A., Alkin, Z., Celik, U., et al. Comparing the effects of three different intravitreal injection techniques on vitreous reflux and intraocular pressure. J. Ocul. Pharmacol. Ther. 29: 325-329, 2013
21. Lorenz, K., Zwiener, I., and Mirshahi, A. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch. Clin. Exp. Ophthalmol. 248: 1573-1577, 2010
22. Woo, S.J., Park, K.H., Hwang, J.M., et al. Risk factors associated with sclerotomy leakage and postoperative hypotony after 23-gauge transconjunctival sutureless vitrectomy. Retina. 29: 456-463, 2009
23. Duval, R., Hui, J.M., and Rezaei, K.A. Rate of sclerotomy suturing in 23-gauge primary vitrectomy. Retina. 34: 679-683, 2014
24. Bamonte, G., Mura, M., and Stevie Tan, H. Hypotony after 25-gauge vitrectomy. Am. J. Ophthalmol. 151: 156-160, 2011
25. Gotzaridis EV. Sutureless transconjunctival 20 gauge pars plana vitrectomy. Semin. Ophthalmol. 22: 179-183, 2007
26. Garay-Aramburu, G., Gómez-Moreno, A ., Urcola, J.A., et al. 22-gauge sclerotomy architecture evaluated by anterior segment optical coherence tomography. Br. J. Ophthalmol. 98: 280-281, 2014
27. Adán, A., Pelegrín, L., Rey, A., et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 33: 1435-1440 2013